Platinum-based chemotherapy for early triple-negative breast cancer

Mason, Sofia RE; Willson, Melina L; Egger, Sam J; Beith, Jane; Dear, Rachel F; Goodwin, Annabel

doi:10.1002/14651858.cd014805.pub2

Cited by 6 publications

(3 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basal-type breast cancers like BRCA1 and BRCA2 mutation and triple-negative cancers are uniquely susceptible to platinum compounds [6]. Commonly, carboplatin is administered intravenously over 25 minutes.…”

Section: Discussionmentioning

confidence: 99%

Carboplatin-Induced Hematuria With Obstructive Acute Kidney Injury

Nallathambi,

Chinnadurai,

2024

Cureus

View full text Add to dashboard Cite

Platinum-based chemotherapeutic agents such as cisplatin, carboplatin, and oxaliplatin are used as adjuvant or neoadjuvant agents in malignancies of the ovary, cervix, lymphoma, head and neck, and breast. Cisplatin is most commonly used until the carboplatin is approved by the Food and Drug Administration (FDA). Cisplatin is not tolerated in many patients due to severe nausea and renal tubular injury. Carboplatin is used in patients where side effects limit the uses of cisplatin. Although carboplatin is least commonly associated with hematuria, we report a case of carboplatin-induced hematuria with obstructive acute kidney injury (AKI). Our patient, a 63-year-old female diagnosed with triple-negative breast carcinoma and postmastectomy, was started on adjuvant chemotherapy, with carboplatin 700 mg and paclitaxel 250 mg. She developed hematuria with ureter obstruction due to clots, resulting in obstructive AKI. The patient continued to have oliguria and worsening symptoms, and thus, the ureter was stented. The patient's renal function returned to the baseline. In this case, we highlight the fact that carboplatin can cause hematuria with ureter obstruction. Adequate hydration before infusing carboplatin as in cisplatin can reduce the complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Carboplatin-Induced Hematuria With Obstructive Acute Kidney Injury

Nallathambi,

Chinnadurai,

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…The cohort of clinically approved platinating derivatives includes cisplatin (CIS), carboplatin (CPT), and oxaliplatin (OXP). The major mechanism of their action is DNA damage followed by the inhibition of transcription, but they are also able to exert cytoplasmic effects such as mitochondrial damage, ER stress, the suppression of ribosome biogenesis, and the elevation of micro-RNA activity [91,92]. They are widely used as a first-line chemotherapy compound for ovarian, cervical, testicular, bladder, esophageal, lung, and head and neck cancers; brain tumors; and neuroblastoma.…”

Section: Chloroquine-and Platinum-based Anticancer Drugsmentioning

confidence: 99%

Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment

Agalakova

2024

IJMS

View full text Add to dashboard Cite

Chloroquine (CQ) and its derivate hydroxychloroquine (HCQ), the compounds with recognized ability to suppress autophagy, have been tested in experimental works and in clinical trials as adjuvant therapy for the treatment of tumors of different origin to increase the efficacy of cytotoxic agents. Such a strategy can be effective in overcoming the resistance of cancer cells to standard chemotherapy or anti-angiogenic therapy. This review presents the results of the combined application of CQ/HCQ with conventional chemotherapy drugs (doxorubicin, paclitaxel, platinum-based compounds, gemcitabine, tyrosine kinases and PI3K/Akt/mTOR inhibitors, and other agents) for the treatment of different malignancies obtained in experiments on cultured cancer cells, animal xenografts models, and in a few clinical trials. The effects of such an approach on the viability of cancer cells or tumor growth, as well as autophagy-dependent and -independent molecular mechanisms underlying cellular responses of cancer cells to CQ/HCQ, are summarized. Although the majority of experimental in vitro and in vivo studies have shown that CQ/HCQ can effectively sensitize cancer cells to cytotoxic agents and increase the potential of chemotherapy, the results of clinical trials are often inconsistent. Nevertheless, the pharmacological suppression of autophagy remains a promising tool for increasing the efficacy of standard chemotherapy, and the development of more specific inhibitors is required.

show abstract

“…In TNBC, the data of adding carboplatin in the adjuvant setting are limited (LoE 1b/B/AGO+) [81], here 18 weeks of paclitaxel/carboplatin have been shown superior DFS compared to three cycles of FEC followed by three cycles of docetaxel. While in the neoadjuvant setting, the addition of carboplatin to anthracyline-/taxane-based treatment has been adopted as a standard treatment, in particular in stage II-III disease which is now supported by a Cochrane metaanalysis [82]. Recently for HER2-negative patients with a high recurrence risk and a germline BRCA1/2 mutation olaparib demonstrates as (postneo) adjuvant therapy (LoE 1b/B/AGO+) an improved iDFS and OS [83].…”

Section: Adjuvant Cytotoxic and Targeted Therapymentioning

confidence: 99%

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

Park-Simon,

Müller,

Albert

et al. 2024

Breast Care

View full text Add to dashboard Cite

Introduction: Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Breast Cancer provides updated state-of-the-art recommendations for early and metastatic breast cancer. Methods: The updated evidence-based treatment recommendations for early and metastatic breast cancer have been released in March 2024. Results and Conclusion: This paper concisely captures the updated recommendations for early breast cancer chapter by chapter.

show abstract

Platinum-based chemotherapy for early triple-negative breast cancer

Cited by 6 publications

References 100 publications

Carboplatin-Induced Hematuria With Obstructive Acute Kidney Injury

Carboplatin-Induced Hematuria With Obstructive Acute Kidney Injury

Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

Contact Info

Product

Resources

About